Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

This study is testing whether low-dose inotuzumab ozogamicin — an antibody-drug that targets leukemia cells — given after a stem cell transplant can prevent acute lymphoblastic leukemia (ALL) from relapsing (coming back) in high-risk patients. **You may be eligible if...** - You are 18 or older - You have been diagnosed with CD22-positive acute lymphoblastic leukemia (B-cell ALL) - You have undergone a stem cell transplant (from a donor or your own cells) - It has been at least 60 days since your transplant - Your leukemia was high-risk, relapsed/refractory, or had detectable residual cancer (MRD positive) before transplant - Your donor chimerism is above 99% (meaning the transplant has successfully engrafted) - Your blood counts have recovered adequately after transplant - Your overall health is adequate (ECOG ≤ 2) **You may NOT be eligible if...** - Your leukemia is progressing at the time of enrollment - You have significant ongoing side effects from prior treatment - Your organ function is too impaired to tolerate the study drug Talk to your doctor to see if this trial is right for you.